Rocket Net Debt To E B I T D A from 2010 to 2024
| RCKT Stock | USD 14.20 0.09 0.64% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.13042743 | Current Value 0.12 | Quarterly Volatility 1.19111733 |
Check Rocket Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rocket Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.5 M, Interest Expense of 3.3 M or Selling General Administrative of 77 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.37. Rocket financial statements analysis is a perfect complement when working with Rocket Pharmaceuticals Valuation or Volatility modules.
Rocket | Net Debt To E B I T D A |
Latest Rocket Pharmaceuticals' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Rocket Pharmaceuticals over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Rocket Pharmaceuticals' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rocket Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Rocket Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 0.74 | |
| Coefficient Of Variation | 160.54 | |
| Mean Deviation | 0.90 | |
| Median | 0.55 | |
| Standard Deviation | 1.19 | |
| Sample Variance | 1.42 | |
| Range | 4.4147 | |
| R-Value | 0.19 | |
| Mean Square Error | 1.47 | |
| R-Squared | 0.04 | |
| Significance | 0.49 | |
| Slope | 0.05 | |
| Total Sum of Squares | 19.86 |
Rocket Net Debt To E B I T D A History
About Rocket Pharmaceuticals Financial Statements
Rocket Pharmaceuticals shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Rocket Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Rocket Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rocket Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.13 | 0.12 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.